A Study of Brivaracetam in Subjects With Partial Onset Seizures
A Study of Brivaracetam in Subjects With Partial Onset Seizures
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150
 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy
Inclusion Criteria:

 -  Well-characterized focal epilepsy or epileptic syndrome according to the International
 League Against Epilepsy (ILAE) classification

 -  Subjects with a history of partial onset seizures

 -  Subjects having at least 4 partial onset seizures during the Baseline period and at
 least 2 partial onset seizures per month during the 3 months preceding Visit 1

 -  Subjects being uncontrolled while treated by 1 or 2 concomitant Antiepileptic drug(s)
 AED(s) being stable

 -  Male/ female subjects from 16 to 65 years, both inclusive. Subjects under 18 years may
 only be included where legally permitted and ethically accepted

 Exclusion Criteria:

 -  Seizure type IA non-motor as only seizure type

 -  History or presence of seizures occurring only in clustered patterns

 -  History of cerebrovascular accident (CVA)

 -  Presence of any sign suggesting rapidly progressing brain disorder or brain tumor